| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine and Oncology, McGill University Health Centre, Montreal, Quebec, Canada H3A 1A1
Address all correspondence and requests for reprints to: Shafaat A. Rabbani, M.D., McGill University Health Centre, 687 Pine Avenue West, Room H4.61, Montreal, Quebec, Canada H3A 1A1. E-mail: shafaat.rabbani{at}mcgill.ca.
We evaluated the capacity of estradiol (E2) to regulate PTHrP production, cell growth, tumor growth, and metastasis to the skeleton in breast cancer. In estrogen receptor (ER)-negative human breast cancer cells, MDA-MB-231, and cells transfected with full-length cDNA encoding ER (S-30), E2 caused a marked decrease in cell growth and PTHrP production, effects that were abrogated by anti-E2 tamoxifen. E2 also inhibited PTHrP promoter activity in S-30 cells. For in vivo studies, MDA-MB-231 and S-30 cells were inoculated into the mammary fat pad of female BALB/c nu.nu mice. Animals receiving S-30 cells developed tumors of significantly smaller volume compared with MDA-MB-231 tumor-bearing animals. This change in tumor volume was reversed when S-30 cells were inoculated into ovariectomized (OVX) hosts. Inoculation of MDA-MB-231 cells into the left ventricle resulted in the development of lesions in femora and tibia as determined by x-ray analysis. In contrast, these lesions were significantly smaller in volume and number in animals inoculated with S-30, and this lower incidence was reversed in OVX animals. Bone histological analysis showed that the tumor volume to tissue volume ratio was comparable with that seen by x-ray. Immunohistochemical analysis showed that PTHrP production was inhibited in S-30 group and restored to levels comparable to that seen in MDA-MB-231 tumor-bearing animals when S-30 cells were inoculated in OVX animals. Collectively these studies show that E2 production is inversely correlated with PTHrP production and that the growth-promoting effect of PTHrP has a direct impact on tumor growth at both nonskeletal and skeletal sites.
This article has been cited by other articles:
 |
|
 |
|
  J. Fuentes, P. M. Guerreiro, T. Modesto, J. Rotllant, A. V. M. Canario, and D. M. Power A PTH/PTHrP receptor antagonist blocks the hypercalcemic response to estradiol-17beta Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R956 - R960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Woodrow, C. J. Sharpe, N. J. Fudge, A. O. Hoff, R. F. Gagel, and C. S. Kovacs Calcitonin Plays a Critical Role in Regulating Skeletal Mineral Metabolism during Lactation Endocrinology, September 1, 2006; 147(9): 4010 - 4021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khalili, A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, F. Donate, D. E. Shaw, A. P. Mazar, and S. A. Rabbani A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther., September 1, 2006; 5(9): 2271 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Cleton-Jansen, H. M. van Beerendonk, H. J. Baelde, J. V.G.M. Bovee, M. Karperien, and P. C.W. Hogendoorn Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma Clin. Cancer Res., November 15, 2005; 11(22): 8028 - 8035. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
